GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.